Resource Summary

Clinical Question:
How does the newer anti-platelet drug ticagrelor (Brillinta®) compare to clopidogrel for post-acute coronary syndrome (ACS)?

Bottom Line:
After ACS^ ticagrelor reduces combined cardiovascular death^ stroke^ and myocardial infarction (MI) about 2 percent more than clopidogrel. Ticagrelor increases a few adverse events^ particularly 6 percent more dyspnea^ and effectiveness remains uncertain in North America.


*** Original Documents can be found and downloaded using the link provided below ***

https://www.acfp.ca/tools-for-practice/

Publication Date: 2014-1-20
Last Updated on PCR: 2017-03-31 16:52:44